Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Daiichinkyo Co's average EBITDA Per Share Growth Rate was -19.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 21.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 29.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Daiichinkyo Co was 47.50% per year. The lowest was -14.30% per year. And the median was 1.05% per year.
Daiichinkyo Co (OTCPK:DSKYF) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Daiichinkyo Co 5-Year EBITDA Growth Rate Related Terms
DSKYF vs LLY, JNJ, ABBV: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's 5-Year EBITDA Growth Rate falls into.
Daiichinkyo Co 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 29.00% mean?
Daiichinkyo Co (DSKYF) has a 5-Year EBITDA Growth Rate of 29.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Daiichinkyo Co and its competitors.
Is Daiichinkyo Co's 5-Year EBITDA Growth Rate too high?
Daiichinkyo Co's current 5-Year EBITDA Growth Rate is 29.00%. Overall, Daiichinkyo Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's 5-Year EBITDA Growth Rate compare to LLY and JNJ?
Daiichinkyo Co's 5-Year EBITDA Growth Rate of 29.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Daiichinkyo Co and its competitors. Daiichinkyo Co's current 5-Year EBITDA Growth Rate is 29.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $31.66, compared to a current price of $18.34 — trading 42.1% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 29.00%. Daiichinkyo Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current 5-Year EBITDA Growth Rate is 29.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $18.34 is trading 42.1% below its estimated GF Value™ of $31.66.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
5-Year EBITDA Growth Rate: 29.00%
GF Value™: $31.66 vs. price of $18.34 (42.1% below fair value)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
79GF Score
Get the complete analysis for DSKYF
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
